119 related articles for article (PubMed ID: 37643638)
21. Financial impact from in-office dispensing of oral chemotherapy.
Howard A; Kerr J; McLain M; Modlin J
J Oncol Pharm Pract; 2019 Oct; 25(7):1570-1575. PubMed ID: 30249154
[TBL] [Abstract][Full Text] [Related]
22. The Influence of Practice Structure on Urologists' Treatment of Men With Low-Risk Prostate Cancer.
Mitchell JM; Gresenz CR
Med Care; 2022 Sep; 60(9):665-672. PubMed ID: 35880758
[TBL] [Abstract][Full Text] [Related]
23. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents.
Hafron JM; Wilfehrt HM; Ferro C; Harmon M; Flanders SC; McKay RR
Adv Ther; 2022 Jun; 39(6):2515-2532. PubMed ID: 35352309
[TBL] [Abstract][Full Text] [Related]
24. Urologists' self-referral for pathology of biopsy specimens linked to increased use and lower prostate cancer detection.
Mitchell JM
Health Aff (Millwood); 2012 Apr; 31(4):741-9. PubMed ID: 22492891
[TBL] [Abstract][Full Text] [Related]
25. Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial.
Vaishampayan UN; Heilbrun LK; Monk P; Tejwani S; Sonpavde G; Hwang C; Smith D; Jasti P; Dobson K; Dickow B; Heath EI; Semaan L; Cher ML; Fontana JA; Chinni S
JAMA Netw Open; 2021 Jan; 4(1):e2034633. PubMed ID: 33496795
[TBL] [Abstract][Full Text] [Related]
26. Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities.
Lu-Yao G; Nikita N; Keith SW; Nightingale G; Gandhi K; Hegarty SE; Rebbeck TR; Chapman A; Kantoff PW; Cullen J; Gomella L; Kelly WK
Eur Urol; 2020 Feb; 77(2):158-166. PubMed ID: 31420248
[TBL] [Abstract][Full Text] [Related]
27. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
28. Urologist Practice Structure and Spending for Prostate Cancer Care.
Modi PK; Herrel LA; Kaufman SR; Yan P; Borza T; Skolarus TA; Schroeck FR; Hollenbeck BK; Shahinian VB
Urology; 2019 Aug; 130():65-71. PubMed ID: 31029672
[TBL] [Abstract][Full Text] [Related]
29. Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy on the Risk of Upgrading in Final Pathology in Prostate Cancer Patients Undergoing Radical Prostatectomy? An European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study.
Zattoni F; Marra G; Martini A; Kasivisvanathan V; Grummet J; Harkin T; Ploussard G; Olivier J; Chiu PK; Valerio M; Marquis A; Gontero P; Guo H; Zhuang J; Frydenberg M; Moon D; Morlacco A; Kretschmer A; Barletta F; Heidegger I; Tilki D; van den Bergh R; Dal Moro F; Briganti A; Montorsi F; Novara G; Gandaglia G;
Eur Urol Focus; 2023 Jul; 9(4):621-628. PubMed ID: 36746729
[TBL] [Abstract][Full Text] [Related]
30. Reimbursement and use of intensity-modulated radiation therapy for prostate cancer.
Shahinian VB; Kaufman SR; Yan P; Herrel LA; Borza T; Hollenbeck BK
Medicine (Baltimore); 2017 Jun; 96(25):e6929. PubMed ID: 28640073
[TBL] [Abstract][Full Text] [Related]
31. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
32. Racial Disparities in Prostate Specific Antigen Screening and Referral to Urology in a Large, Integrated Health Care System: A Retrospective Cohort Study.
Lu CD; Adeyemi O; Anderson WE; Hetherington TC; Slawson DC; Tapp H; Eaton TA; Burgess EF; Grigg CM; Zhu JZ; Gaston KE; Riggs SB; Clark PE; Taylor YJ; Kearns JT
J Urol; 2021 Aug; 206(2):270-278. PubMed ID: 33793294
[TBL] [Abstract][Full Text] [Related]
33. Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices.
Freedland SJ; Richhariya A; Wang H; Chung K; Shore ND
Urology; 2012 Aug; 80(2):293-8. PubMed ID: 22748612
[TBL] [Abstract][Full Text] [Related]
34. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.
Qu F; Xie W; Nakabayashi M; Zhang H; Jeong SH; Wang X; Komura K; Sweeney CJ; Sartor O; Lee GM; Kantoff PW
Clin Cancer Res; 2017 Feb; 23(3):726-734. PubMed ID: 27489290
[TBL] [Abstract][Full Text] [Related]
35. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
36. Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly.
Hollenbeck BK; Kaufman SR; Yan P; Herrel LA; Borza T; Schroeck FR; Jacobs BL; Skolarus TA; Shahinian VB
Eur Urol; 2018 Apr; 73(4):491-498. PubMed ID: 28823605
[TBL] [Abstract][Full Text] [Related]
37. Association Between Private Equity Acquisition of Urology Practices and Physician Medicare Payments.
Nie J; Hsiang W; Lokeshwar SD; McMahon G; Demkowicz PC; Kenney PA; Breyer BN; Leapman MS
Urology; 2022 Sep; 167():121-127. PubMed ID: 35680053
[TBL] [Abstract][Full Text] [Related]
38. Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Bui CN; O'Day K; Flanders S; Oestreicher N; Francis P; Posta L; Popelar B; Tang H; Balk M
J Manag Care Spec Pharm; 2016 Feb; 22(2):163-70. PubMed ID: 27015255
[TBL] [Abstract][Full Text] [Related]
39. Changes in Billing and Reimbursement for Urology Office Visits Before and After Medicare Payment Reforms.
Lee AJ; Saxton A; Hassig S; Quarrier SO; Bandari J
Urol Pract; 2023 May; 10(3):221-228. PubMed ID: 37103502
[TBL] [Abstract][Full Text] [Related]
40. A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer.
McKay RR; Hafron JM; Ferro C; Wilfehrt HM; Fitch K; Flanders SC; Fabrizio MD; Schweizer MT
Adv Ther; 2020 Dec; 37(12):4910-4929. PubMed ID: 33029725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
